Our findings highlight the impact of RT on the systemic T-cell profile and offer potential surrogate markers, such as CCR1-, 4- and/or 5-expressing T cells, which can be tested in clinical trials investigating immunotherapies to improve NPC patient stratification and response monitoring. The gene discussed is CCR1; the disease is nasopharyngeal carcinoma.